Bryce Point Capital LLC Purchases Shares of 1,597 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bryce Point Capital LLC acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,597 shares of the medical research company's stock, valued at approximately $525,000.

Several other large investors have also bought and sold shares of the company. Glenmede Trust Co. NA acquired a new stake in Bio-Rad Laboratories in the 3rd quarter valued at about $351,000. Verition Fund Management LLC increased its holdings in shares of Bio-Rad Laboratories by 193.3% in the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company's stock valued at $1,161,000 after buying an additional 2,287 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at $505,000. Investment Management Corp of Ontario bought a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth $210,000. Finally, Quarry LP boosted its stake in shares of Bio-Rad Laboratories by 38.1% during the 3rd quarter. Quarry LP now owns 297 shares of the medical research company's stock worth $99,000 after acquiring an additional 82 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BIO shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $395.20.

Bio-Rad Laboratories Stock Up 12.6 %

Shares of NYSE BIO traded up $27.71 during mid-day trading on Wednesday, reaching $248.22. The company had a trading volume of 568,099 shares, compared to its average volume of 316,969. The stock has a market capitalization of $6.95 billion, a PE ratio of -3.82 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a twelve month low of $215.38 and a twelve month high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock's 50 day moving average is $269.27 and its 200-day moving average is $315.95.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.